Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
NCT02964338 · Teva Branded Pharmaceutical Products R&D, Inc. · PHASE3 · terminated · last registry update 2021-11-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Futility analysis revealed that the primary endpoint is unlikely to be met. There were no safety concerns observed with fremanezumab treatment in the trial.” | – | Registry record, Teva Branded Pharmaceutical Products R&D, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CALCA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-08-19Results posted on the registry: Eli Lilly and Company, Galcanezumab + Placebo (NCT03963232)
- 2022-07-22Results posted on the registry: H. Lundbeck A/S, Eptinezumab + Placebo (NCT04418765)
- 2022-07-14Phase 3 first posted: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT05458011)
- 2022-04-13Results posted on the registry: David True, Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY] (NCT04461795)
- 2022-03-22Results posted on the registry: Eli Lilly and Company, Galcanezumab + Erenumab (NCT04294147)
- 2022-02-28Also stopped (withdrawn): Mayo Clinic, Fremanezumab + Placebo (NCT04334408)
- 2022-02-10Results posted on the registry: Eli Lilly and Company, Galcanezumab (NCT02797951)
- 2022-01-24Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., LBR-101 High Dose + LBR-101 Low Dose (NCT02025556)
- 2021-12-20Phase 3 first posted: H. Lundbeck A/S, Eptinezumab (NCT05164172)
- 2021-11-09Also stopped (terminated): Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT02945046)
- 2021-11-09Also stopped (terminated): Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab (NCT03107052)
- 2021-11-09Also stopped (withdrawn): Teva Branded Pharmaceutical Products R&D, Inc., fremanezumab (NCT04447729)
- 2021-11-01Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., LBR-101 High Dose + LBR-101 Low Dose (NCT02021773)
- 2021-10-01Phase 3 first posted: H. Lundbeck A/S, Eptinezumab (NCT05064371)
- 2021-10-01Phase 3 first posted: H. Lundbeck A/S, Eptinezumab (NCT05064397)
- 2021-08-16Results posted on the registry: H. Lundbeck A/S, Eptinezumab + Placebo (NCT04152083)
- 2021-07-16Phase 3 first posted: H. Lundbeck A/S, Eptinezumab + Placebo (NCT04965675)
- 2021-07-16Results posted on the registry: Otsuka Pharmaceutical Co., Ltd., TEV-48125 + TEV-48125 (NCT03303105)
- 2021-07-08Results posted on the registry: Otsuka Pharmaceutical Co., Ltd., TEV-48125 + TEV-48125 or placebo (NCT03303092)
- 2021-06-15Results posted on the registry: Otsuka Pharmaceutical Co., Ltd., TEV-48125 + TEV-48125 or placebo (NCT03303079)
- 2021-06-15Results posted on the registry: Eli Lilly and Company, Galcanezumab + Placebo (NCT04085289)
- 2021-06-10Phase 3 first posted: H. Lundbeck A/S, Placebo + Eptinezumab (NCT04921384)
- 2021-03-26Results posted on the registry: Teva Branded Pharmaceutical Products R&D, Inc., Fremanezumab + Placebo (NCT03347188)
- 2021-03-10Results posted on the registry: Allergan, Ubrogepant + Erenumab (NCT04179474)
- 2021-02-26Phase 3 first posted: H. Lundbeck A/S, Placebo + Eptinezumab (NCT04772742)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision